Stefan Oelrich

Stefan Oelrich is a board member at Bayer, specifically involved with the company's pharmaceutical division. He is newsworthy because Bayer's pharmaceutical division is performing better than expected despite expiring patents on blockbuster drugs. Oelrich highlights the division's strong portfolio, which the board considers the most powerful in its history. The articles suggest that Oelrich is playing a key role in navigating the challenges and opportunities presented by this period of growth and patent expirations. The articles mention a story Oelrich is now ready to share, suggesting a significant event or experience from his time at Bayer, which began in September 2018. His leadership is crucial as Bayer manages high expectations and potential risks associated with its pharmaceutical growth.